Inside DINAMIQS cGMP manufacturing facility for viral vectors
The new facility enables end-to-end manufacturing of viral vector gene therapies, from molecule design to aseptic drug product filling, integrating R&D, clinical, and commercial manufacturing under one roof
Reexamining process optimization: Advanced analytics for AAV manufacturing
Navigating the complexities of rAAV vector manufacturing can be daunting for small and mid-sized biotech companies venturing into the exciting world of gene therapy. Ensuring consistent quality and optimizing production processes are paramount for success.
Though viral vectors are used extensively in cell and gene therapy, the challenges of manufacturing such complex biologics at commercial scale is still a limitation to its broader use. Dr. Eduard Ayuso discusses how DINAMIQS overcomes these challenges.
